Department of Health and Human Services June 8, 2012 – Federal Register Recent Federal Regulation Documents
Results 1 - 12 of 12
Medicare Program; Proposal Evaluation Criteria and Standards for End Stage Renal Disease (ESRD) Network Organizations
This notice describes the standards, criteria, and procedures we will use to evaluate an End-Stage Renal Disease (ESRD) Network Organization's capabilities to perform, and actual performance of, the duties and functions under the ESRD Network Statement of Work (SOW).
Medicare Program; Meeting of the Medicare Economic Index Technical Advisory Panel-June 25, 2012
This notice announces that a public meeting of the Medicare Economic Index Technical Advisory Panel (``the Panel'') will be held on Monday, June 25, 2012. The purpose of the Panel is to review all aspects of the Medicare Economic Index (MEI). This second meeting will focus on MEI price-measurement proxies and the index's productivity adjustment. This meeting is open to the public in accordance with the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)).
Determination of Regulatory Review Period for Purposes of Patent Extension; KALBITOR; Correction
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of May 2, 2012 (77 FR 26017). The document concerned FDA's determination of the regulatory review period for KALBITOR. The document published with an incorrect patent number for KALBITOR. This document corrects that error.
Pfizer, Inc.; Withdrawal of Approval of Familial Adenomatous Polyposis Indication for CELEBREX
The Food and Drug Administration (FDA) is withdrawing approval of the familial adenomatous polyposis (FAP) indication for CELEBREX (celecoxib) Capsules held by Pfizer, Inc. (Pfizer), 235 East 42nd St., New York, NY 10017-5755. Pfizer has voluntarily requested that approval of this indication be withdrawn, thereby waiving its opportunity for a hearing.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
